Search for: "State v. Bristol-Myers Squibb Company " Results 41 - 60 of 159
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
28 Aug 2018, 12:16 am by Julius Stobbs
  Case law states that a brand owner can oppose a repackaging of a pharmaceutical product if the repackaging threatens the guarantee of origin, unless certain conditions are met (as laid out in the cases Bristol-Myers Squibb (see C-427/93, C-429/93 and C-436/93) and Boehringer Ingelheim (see C348/04)). [read post]
23 Aug 2018, 3:00 am by Daniel E. Cummins
The court provided a detailed summary of the current status of the law pertaining to personal jurisdiction based upon a review of several notable United States Supreme Court Opinions, the most recent of which was in the case of Bristol-Myers Squibb Co. v. [read post]
12 Jun 2018, 6:56 am by Joy Waltemath
The agency’s argument that the regulation leaves the decision up to the employer was unavailing, the court explained, under the competitor standing doctrine and had already been rejected in earlier cases, such as Bristol-Myers Squibb Co. v. [read post]
14 Dec 2017, 10:48 pm by GJEL
The remaining manufacturers, including Bristol-Myers Squibb, ultimately settled for $3.4 billion, and Dow Corning resolved its claims in bankruptcy court. [read post]
15 Aug 2017, 4:02 am by Edith Roberts
” In an op-ed at STAT, Michael Burg weighs in on the court’s recent opinion in Bristol-Myers Squibb Co. v. [read post]
15 Aug 2017, 3:02 am by Walter Olson
Following the Supreme Court’s ruling in TC Heartland v. [read post]
27 Jun 2017, 8:00 am by The Editors
On June 19, 2017, the Supreme Court reinforced its narrow application of specific jurisdiction in mass tort proceedings in an 8-1 decision in Bristol-Myers Squibb Company v. [read post]